Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
Steven A BuechlerKathryn P GrayYesim Gökmen-PolarScooter WillisBeat ThürlimannRosita KammlerGiuseppe VialeBrian Leyland-JonesSunil S BadveMeredith M ReganPublished in: JNCI cancer spectrum (2019)
This study confirmed the prognostic significance of EarlyR using RNA from formalin-fixed, paraffin-embedded tissues from a case-cohort sample of BIG 1-98. EarlyR identifies a set of high-risk patients with relatively poor prognosis who may be considered for additional treatment. Further studies will focus on analyzing the predictive value of EarlyR signature.
Keyphrases
- phase iii
- poor prognosis
- early breast cancer
- double blind
- open label
- clinical trial
- placebo controlled
- long non coding rna
- phase ii
- genome wide
- big data
- gene expression
- early stage
- study protocol
- randomized controlled trial
- machine learning
- copy number
- estrogen receptor
- positive breast cancer
- dna methylation
- adipose tissue
- metabolic syndrome
- case control
- breast cancer cells
- skeletal muscle
- smoking cessation